EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study

Kazuhiro Toyota, Kazuaki Tanabe iD, Mikihiro Kano, Toshiaki Komo, Ryuichi Hotta, Senichiro Yanagawa, Yoshihiro Saeki, Hirofumi Tazawa, Masahiro Ikeda, Masayuki Shishida, Keisuke Okano, Ryuta Ide und 4 weitere

Gastric Cancer · 2025

DOI: 10.1007/s10120-024-01563-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Gastric Cancer, 2025. Verfasst von Kazuhiro Toyota und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hiroshima Memorial Hospital, 1-4-3, Honkawa-cho, Naka-ku, Hiroshima, Hiroshima, 730-0802, Japan. Hauptthemen laut MEDLINE: Docetaxel, Stomach Neoplasms, Tegafur, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant docetaxel plus S1 (DS) chemotherapy after gastrectomy with D2 lymph node dissection is the standard treatment for stage III gastric cancer in Japan; however, some patients are unable to receive adequate drug administration because of the deterioration of their conditions. This study aimed to investigate the correlation between tolerability for postoperative adjuvant DS chemotherapy and prognosis, and the factors affecting tolerability.

Methods

This retrospective study involved patients with stage III gastric cancer who underwent curative resection between 2018 and 2021 from a multicenter database. Patients with a cumulative dose of docetaxel and S1 greater than 120 and 8400 mg/m 2 , respectively, were considered tolerable. The prognostic impact and factors predicting tolerability were analyzed.

Results

Of the 103 patients, the tolerable group comprised of 63 (61%) patients and had a significantly better 3-year recurrence-free survival than the intolerable group (83% vs. 64%, P = 0.02). Among the preoperative factors, only performance status (PS, P = 0.04) was significantly correlated with tolerability in the univariate analysis. Among the postoperative factors, PS (P = 0.001) and perioperative weight loss rate (P = 0.02) were significantly correlated with tolerability in the univariate analysis. The multivariate analysis showed significant differences in the PS (odds ratio [OR]: 4.94, 95% confidence interval [CI] 1.79–14.98, P = 0.002) and weight loss rate (OR: 1.10, 95% CI 1.01–1.21, P = 0.03).

Conclusions

Tolerance to postoperative adjuvant DS chemotherapy has a significant prognostic impact. Postoperative PS and perioperative weight loss rates were independent predictors of tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelStomach NeoplasmsTegafurAntineoplastic Combined Chemotherapy ProtocolsOxonic AcidGastrectomyDrug CombinationsHumansRetrospective StudiesMaleFemaleChemotherapy, AdjuvantAgedMiddle AgedPrognosisAdultAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

Adjuvant chemotherapyDocetaxelGastric cancerS1Tolerability

Substanzen

DocetaxelTegafurOxonic AcidS 1 (combination)Drug Combinations

Autor:innen und Institutionen

  • Department of Surgery, Hiroshima Memorial Hospital, 1-4-3, Honkawa-cho, Naka-ku, Hiroshima, Hiroshima, 730-0802, Japan.
  • Department of Perioperative and Critical Care Management, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. ktanabe2@hiroshima-u.ac.jp.
  • Department of Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
  • Department of Surgery, JA Hiroshima General Hospital, Hatsukaichi, Japan.
  • Department of Surgery, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
  • Department of Surgery, JA Onomichi General Hospital, Onomichi, Japan.

ORCID-Profile: Kazuaki Tanabe

Förderung

  • Hiroshima University

Zitieren

APA

Toyota, K., Tanabe, K., Kano, M., Komo, T., Hotta, R., Yanagawa, S., Saeki, Y., Tazawa, H., Ikeda, M., Shishida, M., Okano, K., Ide, R., Imaoka, Y., Takahashi, S., Ohdan, H., & Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) (2025). Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study. Gastric Cancer. https://doi.org/10.1007/s10120-024-01563-w

Vancouver

Toyota K, Tanabe K, Kano M, Komo T, Hotta R, Yanagawa S, et al. Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study. Gastric Cancer. 2025. doi:10.1007/s10120-024-01563-w

BibTeX
@article{Toyota2025,
  author = {Toyota, Kazuhiro and Tanabe, Kazuaki and Kano, Mikihiro and Komo, Toshiaki and Hotta, Ryuichi and Yanagawa, Senichiro and Saeki, Yoshihiro and Tazawa, Hirofumi and Ikeda, Masahiro and Shishida, Masayuki and Okano, Keisuke and Ide, Ryuta and Imaoka, Yasuhiro and Takahashi, Shinya and Ohdan, Hideki and Hiroshima Surgical Study Group of Clinical Oncology (HiSCO), Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)},
  title = {Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-024-01563-w}
}
Kostenlos starten →